After Hours
$
94.65
Change
0.00 0.00%
Volume
Volume 61,578
Nov 27, 2023, 7:41 p.m.
Quotes are delayed by 20 min
Previous close
$ 98.34
$ 94.65
Change
-3.69 -3.75%
Day low
Day high
$94.54
$97.80

52 week low
52 week high
$89.00
$238.55

Market cap
$15.62B
Average volume
2.39M
P/E ratio
N/A
Rev. per Employee
$388,261
EPS
-7.12
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on ILMN
-
Illumina Inc. stock underperforms Monday when compared to competitors
- MarketWatch Automation
-
Illumina Inc. stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Illumina Inc. stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Illumina Inc. stock falls Tuesday, underperforms market
- MarketWatch Automation
-
Illumina Inc. stock outperforms market on strong trading day
- MarketWatch Automation
-
Illumina Inc. stock underperforms Friday when compared to competitors
- MarketWatch Automation
-
Illumina Inc. stock underperforms Thursday when compared to competitors
- MarketWatch Automation
-
Illumina Inc. stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Illumina Inc. stock rises Tuesday, outperforms market
- MarketWatch Automation
-
Illumina Inc. stock underperforms Monday when compared to competitors
- MarketWatch Automation
-
Illumina Inc. stock underperforms Friday when compared to competitors
- MarketWatch Automation
-
Illumina Stock Is the Worst Performer in the S&P 500. Here's Why.
- Barron's Online
-
Illumina shares fall as company cuts forecasts
- Bill Peters
-
Illumina Inc. stock falls Thursday, underperforms market
- MarketWatch Automation
- Loading more headlines...
Analyst Ratings
-
Cynosure Headwinds Trigger Analyst Downgrades on HOLX Stock
- MarketRealist.com
-
Analysts Project ~16.5% Upside in Hologic Stock
- MarketRealist.com
-
7 Biggest Price Target Changes For Tuesday
- Benzinga.com
Other News on ILMN
-
- The Wall Street Journal Interactive Edition
-
Stocks Rise, Booking Weekly Gains
- The Wall Street Journal Interactive Edition
-
Illumina Ordered by EU to Unwind Grail Acquisition
- The Wall Street Journal Interactive Edition
-
Illumina Names New Chief Executive
- The Wall Street Journal Interactive Edition
-
For This Venture Capitalist, Research on Aging Is Personal; ‘Bob Has a Big Fear of Death’
- The Wall Street Journal Interactive Edition
-
Carl Icahn Should Be Sailing Into the Sunset. Instead, He’s Scrambling to Save His Empire.
- The Wall Street Journal Interactive Edition
-
Icahn’s Firm Cuts Dividend in Half After Activist Pressure
- The Wall Street Journal Interactive Edition
-
AI-Generated Data Could Be a Boon for Healthcare—If Only It Seemed More Real
- The Wall Street Journal Interactive Edition
-
Illumina Fined More Than $400 Million in Europe for Closing Grail Deal Early
- The Wall Street Journal Interactive Edition
-
Lina Khan Whiffs on the Microsoft-Activision Tie-Up
- The Wall Street Journal Interactive Edition
-
Icahn Gets Breathing Room Following Short-Seller Attack
- The Wall Street Journal Interactive Edition
-
The Score: Carnival, Disney, Nvidia and More Stocks That Defined the Week
- The Wall Street Journal Interactive Edition
-
Lina Khan Wins as Illumina’s CEO Resigns
- The Wall Street Journal Interactive Edition
-
After Illumina CEO’s Fall, Other Executives May Take Hard Look Before Deal Making
- The Wall Street Journal Interactive Edition
-
Illumina CEO Francis deSouza Resigns
- The Wall Street Journal Interactive Edition
-
Blood-Test Customers Mistakenly Told They May Have Cancer
- The Wall Street Journal Interactive Edition
-
Icahn Nominee Elected to Illumina’s Board
- The Wall Street Journal Interactive Edition
-
Activist Investor Calls on Yelp to Explore Sale
- The Wall Street Journal Interactive Edition
-
Icahn Is No Saint, but Illumina Can Still Use a Flawed Savior
- The Wall Street Journal Interactive Edition
-
FTC Moves to Block Amgen’s $27.8 Billion Deal for Horizon Therapeutics
- The Wall Street Journal Interactive Edition
- Loading more headlines...
Press Releases on ILMN
-
Illumina's genomic technologies enable better pathogen preparedness and response
- PR Newswire - PRF
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com